Irena Webster

Irena Webster is a seasoned global drug development leader with 20 years of industry, CRO, and site-level experience. Throughout her career, Irena has led global trial execution in cardiovascular disorders, oncology, rare diseases, and central nervous system disorders, contributing to multiple NDAs. Prior to joining Arkuda, she served as Vice President of Development Operations for FORMA Therapeutics, where she led the Clinical Operations and Biometrics teams across multiple oncology and rare hematological disease indications, including a successful NDA submission and subsequent approval of olutasidanib for the treatment of IDH1 mutation Acute Myloide Lukemia. Before that, Irena was Director of Early Clinical Development Operations at Sage Therapeutics, where she worked closely with lead optimization, translational, and medical teams focused on experimental medicine, including signal-finding trials and biomarker development in neurological disorders and rare disease. She also formerly worked at Alkermes where she was the clinical operations lead on multiple clinical programs across depression, schizophrenia, addiction and reward disorders. Irena received her MPH from New York Medical College.